|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.960 USD | -1.00% |
|
-2.59% | -7.38% |
| Capitalization | 182M 131M 112M 105M 97.46M 11.82B 196M 1.21B 474M 5.65B 491M 481M 20.83B | P/E ratio 2025 * |
-5.9x | P/E ratio 2026 * | -4.87x |
|---|---|---|---|---|---|
| Enterprise value | 182M 131M 112M 105M 97.46M 11.82B 196M 1.21B 474M 5.65B 491M 481M 20.83B | EV / Sales 2025 * |
11.7x | EV / Sales 2026 * | 5.42x |
| Free-Float |
88.93% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Alpha Cognition Inc.
More press releases
| 1 day | -1.00% | ||
| 1 week | -2.59% | ||
| Current month | -7.38% | ||
| 1 month | +13.37% | ||
| 3 months | -14.55% | ||
| 6 months | -44.34% | ||
| Current year | -7.38% |
| 1 week | 5.85 |  | 6.75 |
| 1 month | 4.99 | | 6.91 |
| Current year | 5.85 | | 6.75 |
| 1 year | 3.75 | | 11.54 |
| 3 years | 3.5 | | 18.5 |
| 5 years | 3.5 | | 45 |
| 10 years | 3.5 | | 45 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael McFadden
CEO | Chief Executive Officer | 59 | 12/04/2021 |
Denis Kay
CTO | Chief Tech/Sci/R&D Officer | - | 22/03/2021 |
Henry Du
DFI | Director of Finance/CFO | - | 21/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Len Mertz
CHM | Chairman | - | 22/03/2021 |
Phillip Mertz
BRD | Director/Board Member | - | 22/03/2021 |
Rajeev Bakshi
BRD | Director/Board Member | 66 | 22/03/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.00% | -2.59% | -1.15% | +5.43% | 131M | |
| +0.02% | +1.24% | +35.07% | +197.88% | 964B | |
| +0.42% | +4.33% | +47.89% | +23.19% | 515B | |
| +0.60% | -1.42% | +24.90% | +43.72% | 390B | |
| +1.11% | +1.69% | +30.56% | +16.73% | 363B | |
| +2.06% | +0.48% | +34.45% | +22.40% | 292B | |
| +1.92% | +1.53% | +28.00% | +33.77% | 272B | |
| +0.17% | -0.56% | +7.21% | -3.55% | 269B | |
| -1.42% | +3.17% | -36.18% | -20.65% | 265B | |
| -0.10% | -1.78% | +20.03% | +19.35% | 175B | |
| Average | +0.38% | +0.95% | +19.08% | +33.83% | 350.52B | |
| Weighted average by Cap. | +0.46% | +1.56% | +26.47% | +68.07% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 15.5M 11.16M 9.59M 8.94M 8.31M 1.01B 16.72M 103M 40.39M 482M 41.84M 40.99M 1.78B | 33.53M 24.13M 20.74M 19.34M 17.97M 2.18B 36.15M 222M 87.36M 1.04B 90.5M 88.65M 3.84B |
| Net income | -24.78M -17.83M -15.32M -14.29M -13.28M -1.61B -26.71M -164M -64.55M -770M -66.88M -65.5M -2.84B | -37.48M -26.98M -23.18M -21.62M -20.09M -2.44B -40.42M -249M -97.65M -1.16B -101M -99.1M -4.29B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
-
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/01/26 | 6.020 $ | -1.15% | 88,218 |
| 12/01/26 | 6.090 $ | -6.74% | 136,156 |
| 09/01/26 | 6.530 $ | -0.46% | 57,512 |
| 08/01/26 | 6.560 $ | +0.92% | 24,541 |
| 07/01/26 | 6.500 $ | +5.18% | 44,278 |
Delayed Quote Nasdaq, January 14, 2026 at 01:00 am
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.020USD
Average target price
20.00USD
Spread / Average Target
+232.23%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ACOG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition